Merck/MSD announced China approval of Keytruda, the company’s anti-PD-1 immunotherapy, as a first-line monotherapy to treat advanced or metastatic non-small cell lung cancer without chemotherapy. Previously, China’s NMPA approved Keytruda as a first line NSCLC treatment together with chemotherapy, and in 2018, it was approved in China as a second-line treatment for metastatic myeloma. Merck said Keytruda caused a statistically significant improvement in overall survival compared to chemotherapy in a China extension of a global NSCLC trial.
Source: China Biotoday
